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The Brookhaven National Laboratory Cosmotron was used to produce 2.2 GeV protons
for total-body exposure of young, female Sprague-Dawley rats. A single exposure of
42-day old rats to 92 rads of protons produced a marmnary neoplastic response over a
365-day period that was qualitatively and quantitatively similar to the response
produced by 158 rads of 60Co gamma rays. When the two types of radiation exposures
were combined they appeared to produce an additive mammary neoplastic response.
Because of the qualitative similarity of the mammary neoplastic response to the
2 types of radiation and because the 2 types of radiation appeared to be additive,
it was suggested that 2.2 GeV protons act by a mode of action that is similar to
that of low LET radiation. Acute radiation mortality produced by a single exposure
of 42-day old rats to protons was qualitatively similar in terms of mean survival
time to mortality produced by 60Co gamma rays. It was suggested that 2.2 GeV protons
act to produce acute radiation mortality in fashion similar to that of low LET radia-
tion. The administration of a radioprotective drug, AET, to 36-day old rats produced
a small decrease in radiation mortality and a small increase in mean survival time
when the drug was given before exposure to 2.2 GeV protons. This result was taken
to mean that 2.2 GeV protons act at least in part as low LET radiation. Although
exact RBE values could not be determined for acute mortality and carcinogenesis in
the young rat, approximate values appear to be 1.4 and 1.5.
INTRODUCTION
When the 2.2 GeV proton facility of the Brook-
haven Cosmotron became available for biological
studies, proton carcinogenesis, the interaction of
protons and gamma-rays on carcinogenesis, proton-
induced acute mortality, and chemical protection
against proton-induced acute mortality were studied
in the rat and these proton-produced responses were
compared to similar responses produced by gamma-
rays or x-rays.
MATERIALS AND METNODS
Animals - Weanling, lltter-mate, female,
Sprague-Dawley rats were obtained from Sprague-
Dawley, Inc., Madison, Wisconsin. All rats were
kept at the University of Michigan until they were
approximately 35 days of age when they were taken
to Brookhaven National Laboratory, exposed and re-
turned to the University of Michigan. Litter-mates
were assigned to each experimental and control
group so that approximately equal numbers of litter
mates were placed in each group. Animals to be
studied for mammary neop!asia were handled as des-
cribed previously (ref. I) for 365 days post-expos-
ure when all animals alive were killed. All anim-
als were examined frequently for mammary tumors and
as these were found, they were removed, sectioned
and given a pathologic classification. Animals
used for acute mortality studies were followed for
30 days and deaths were recorded as to the nearest
day post-exposure. Chemical protection studies
were done by injecting 2-aminoethylisothiouronium
bromide (AET), 30 mg per rat by the intraperitoneal
route, 15 minutes before exposure.
EXPOSURE CONDITIONS
Protons of 2.2 GeV, produced by the Brookhaven
Cosmotron were used to expose rats in exactly the
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same way as described previously for mice (ref. 2)
except that the inside diameter of the lucite tube
holding the animals was increased to 4.5 cm and a
length of 50 cm. Four rats were exposed per Cosmo-
iron run, nose to tail, with the nose facing the
stream of protons. As a check on a possible change
in dose with position of the rat within the expos-
ure tube, or change of dose with depth, rat position
in the tube was recorded and checked against indiv-
idual and group rat mortality. The exposure tube
holding the rats was placed well within the beam of
protons and parallel with the beam as determined by
means of a fore and aft gun sight array and Polar-
oid film. The animals in the exposure tube were
rotated along their longitudinal axis at 20 rpm to
insure a uniform dose distribution. The Cosmotron
beam pulse duration was i msec and the repetition
rate was 25 pulses per minute. With the proton
fluence employed, the instantaneous dose rate was
14 k rads/sec or an average dose rate of 350 rads/
min.
Gamma-ray exposures were done at a dose rate
of 14 R/min. X-ray exposures were accomplished by
operating a conventional x-ray therapy machine at
250 kVp and 30 mA with 0.5 mm Cu and i mm Ai added
filtration at a dose rate of 115 R/min.
DOSIMETRY
Each proton irradiation run was monitored by
use of the proton activation of the 12C in a poly-
ethylene foil via the reaction 12C (p,np) IIc as
described previously (ref. 2). The foils were
calibrated in terms of dose by means of a tissue
equivalent ionization chamber (ref. 3). The foil
fluence determination and the dosimetry yielded a
result of 354 rads (I) per i0 I0 protons/cm 2.
For x-rays and gamma-rays, the exposure dose
was measured in air at the dorsal-ventral mid-
point of the animals with a Victoreen ionization
chamber in R and these values were converted to rad
values, using a physical factor of 0.95 to convert
(1)W. H. Moore, Erookhaven calculated, for primary ionization,
16, 13, 1969), for total absorbed dose, 410 rads.
R to rads and a biological factor of 0.83 (ref. 4)
to relate 60Co gamma-rays to 250 kVp x-rays.
EXPERIMENTS
Carcinogenesis. Forty-two day old rats were
exposed to 92 rads of 2.2 GeV protons, or 158 rads
of 60Co gamma-rays, or both. The gamma-ray expos-
ure was done approximately 12 hours before the pro-
ton exposure.
Acute mortality. Forty-two day old rats were
exposed to 473, 600, 661 or 729 rads of 60Co gamma-
rays or 354, 478, 595 or 715 rads of 2.2 GeV proton.
Chemical protection. Thirty-six day old rats
were exposed to 712 fads of 250 kVp x-rays with or
without prior AET, or 527, 552, 577 or 602 rads of
2.2 GeV protons with or without prior AET.
RESULTS
The mammary neoplastic response to 92 rads of
proton exposure, or 158 fads of gamma exposure, or
both types of radiation are presented in Table I
along with mammary neoplastic incidence of non-
irradiated litter-mate controls. It seems clear
that all measures of mammary neoplasia incidence
are approximately the same in response to either 92
rads of proton exposure or 158 rads of 60Co gamma
exposure. Although the value is somewhat uncertain
the approximately equal effects of doses of 92 rads
from protons and 158 rads from gammas, yield a RBE
of about 1.5 using a linear dose-response relation-
ship for each type of radiation and subtraction of
control values.
When the proton exposure was combined with the
gamma-ray exposure, the percent of rats with mam-
mary neoplasia was not very informative because the
dose of each radiation that was selected when com-
bined appears to saturate this measure of mammary
neoplastic response. However, the measures of
total number of mammary neoplasms, or total number
of mammary adenocarcinomas, or the total number of
mammary fibroadenomas, when each is corrected for
number of rats at risk, appear to indicate that
332 rads and Wright et al.(Health Physics
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Table i
MamB.IryNeoplasla and Ma_ry Neoplasm at 300 Days Post-Exposure.
Exposures Done st 42 Days of Age. 6%o Ga_ 3×posure Preceded
Proton Expo.ure by 12 _oura. A¢ Refers to Adenocar¢in_ a.d FA
Refers to Flbroadeno_.
Treat_nt Rats with Mammary
Neoplaala
Kadlatlon Pads N N %
_4a_ry Neoplasm
Total AC FA
Total _ Ac _- _A N--
N_a 22 1 4 1 0.04 1 O.04 0 0
Proton 92 32 14 44 20 .62 4 .12 16 0.50
60Co p 158 32 t6 50 23 .72 4 ,12 19 .59
Proton +
60Co _ 250 28 19 68 37 1.32 8 .29 23 1.00
proton irradiation and gamma-ray irradiation are
very close to being additive. This result implies
that the mechanism of action of the 2 types of rad-
iation are similar.
The results of studies on acute mortality in
terms of percent dead within 30 days, and the mean
survival time are shown in Table 2. Within the
lethal range of doses, the mean survival times are
about the same for the 2 types of radiation and
this implies that proton exposure or gamma-ray
exposure produces acute mortality by a similar
mechanism. Because the number and the range of
doses of each type of radiation is small, and the
sample size is not large, a value for RBE cannot be
given with any high degree of confidence. However,
if these data are plotted, and a visual fit of the
survival curves are drawn, and the ratio of LD50
values is determined, the proton exposure rad for
rad appears to be about 1.4 times more potent than
for the gamma-ray exposure.
Table 2
Acute Radiation Mortality, Nmsber of Anlslll Expond
at 42 Day8 o_ _e, Perc_t 30-Day Survival and Mean
Survival Tim in Days of Decedents.
Radiation IUsd____s N % D_sd 14. S. T.
6OCo y 473 9 0
60Co _ 600 9 56 16.4
60Co _ 661 9 78 17.4
60Co _" 729 10 100 10.7
Protoa 3_ 12 33 21.0
Protc_ 478 12 6? 17. $
Pzotou 595 12 100 9.8
protoa 715 I2 lO0 4.5
The data concerned with the radioprotective
action of AET are shown in Table 3. Although all
exposure doses used proved to be lethal in the ab-
sence of the drug, AET produced a small protective
effect against mortality in the 2 lowest doses of
proton exposure and the x-ray exposure. A modest
increase in mean survival time was produced by AET
at all proton exposure doses and the single x-ray
dose. It thus appears that AET does have the cap-
acity to protect against acute radiation mortality
provoked by 2.2 GeV proton exposure.
Analysis of the position of the rat in the ex-
posure tube by using days of survival time disclos-
ed that survival time increased as the position was
moved downstream. This increase was related to
reduction in dose - produced increased survival
time. This indicates that the decrease in dose
received by the last rat downstream is no less than
72% of the first rat and is in agreement with inter-
posed ionization chamber measurements where the
dose decreased to 64/°.
Table 3
Acute Radiation Mortality, Number of Rats Exposed
at 36 Days of Age, Percent 30-Day Survival and
Mean Survival Time in Days of Decedents. AET
Injected by Subcutaneous Route 15 Minutes
Before Exposure.
Radiation
X-Ray
X-Ray
Proton
Proton
Proton
Proton
Proton
Proton
Proton
Proton
Rads Drug N % Dead M.S.T.
712 i0 i00 5.4
712 AET I0 80 9.4
527 12 I00 8.2
527 AET 12 75 9.7
552 12 I00 7.2
552 AET 12 92 9.4
577 12 I00 6.1
577 AET 12 i00 9.7
602 12 I00 5.3
602 AET 12 100 8.2
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DISCUSSION
The results here presented are perhaps of
more qualitative interest than of quantitative in-
terest. Although only a single proton dose was
tested, it is clear that 2.2 GeV protons have the
capacity to accelerate the rat mammary neoplastic
response and that this proton-induced mammary neo-
plastic response is qualitatively similar to the
mammary neoplastic response to gamma radiation.
This finding confirms a preliminary report (ref. 5)
that indicated that the mananary neoplastic response
to 2.2 GeV protons and 60Co gamma-rays was qual-
itatively similar. Strengthening the conclusion
that either proton exposure or gamma-ray exposure
produces a qualitatively similar mammary neoplastic
response is the finding that when the two types of
exposure were combined an additive result ensued.
It has been shown previously that x-rays (ref. 6)
and protons (ref_ 5) produce a linear dose-response.
The 12-hour gap between gamma-ray exposure and pro-
ton exposure in the experimental group that received
both types of exposure probably is of no biological
consequence since it has been shown that the inci-
dence of mammary neoplasia of the rat is little
changed by short-term fractionation of sub-lethal
total body x-ray exposure (ref. 7). It is not un-
reasonable to suggest, therefore, that the mechanism
of action that allows proton exposure to be carcino-
genic is not dissimilar to the mechanism of action
that allows gamma-ray exposure to be carcinogenic.
ozLi_= _n_L/a-£ay_ a£_ £uw _I _aulaLlon, then 2.2
GeV protons should he considered to act, in a large
part, as low LET radiation.
It seems clear, also, that 2.2 GeV proton
exposure produces an acute radiation mortality that
is qualitatively similar to that produced by gamma-
ray exposure. Again, it is tempting to suggest that
2.2 GeV protons act by a mechanism that is similar
to low LET radiation. Adding to this suggestion was
the absence of high LET "early death" that has been
reported by others who have noted a shift from
marrow to gut death with high LET radiations (ref.
8).
It is generally accepted that radioprotective
compounds are more effective against low LET radia-
tion than against high LET radiation (ref. 9).
Thus, the finding of a small hut definite protec-
tion with AET against acute mortality as produced
by 2.2 GeV protons may be taken to indicate that
these protons act, at least in part, as low LET
radiation.
The finding that it is possible to protect
against acute radiation mortality as produced by
high energy protons by prior AET treatment may be
of some interest to those who are concerned with
astronauts and their possible exposure to high ener-
gy protons. The data here reported are, we believe,
the only direct experimental test reported on this
subject, and are of some academic interest.
The interrelation between 2.2 GeV proton-pro-
duced radiation carcinogenesis and acute mortality
is of some radiobiological interest. There is no
priori reason to expect that the relative biolog-
ical effectiveness of minimum ionizing protons
would be the same for tumor induction as it is for
inducing mortality because the induction of a tumor
must depend upon the number of cells that ar___e cap-
able of division after radiation exposure (ref. i0)
while the production of acute radiation mortality
depends upon the number of cells of the blood form-
ing organs and the gastrointestinal tract that are
not capable of division after radiation exposure
(ref. II). Thus, the finding that the relative
biological effectiveness of 2.2 GeV protons was,
within the limits of the two experiments, not very
different on these two dissimilar biological end-
points was somewhat surprising.
Data published dealing with the biological
effects of high energy protons are not extensive.
Ueno and Grigoriev (ref. 12) have summarized data
dealing with proton energies between 126 MeV and
730 MeV on 52 experiments in mammals including
cytological changes, organ atrophy and acute mort-
ality. They believe that a single value of RBE,
0.82 _ 0.04 can be assigned to all of these end
points. On the other hand, for 2.2 GeV protons,
the results are not so clear. Jesseph et al. (ref.
2) reported an RBE value of 0.87 for acute mortal-
ity in the mouse. Montour, et al. (ref. 13) using
mice and spleen-thymus weight loss at 2-3 and 4-5
days after exposure and the same exposure condition
and dose measurements of Jesseph et al., obtained
RBE values of approximately 1.0. Stoner, et al.
(ref. 14) using mice and the same exposure condi-
tions of Jesseph, et al. obtained a value of 2.5
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for the repression of primary tetanus antitQxin
responses, 1.5 for secondary responses and 1.5 for
enhanced susceptibility to anaphylaxis. Thus, in
mice, using similar exposure conditions, RBE values
ranging from 0.87 to 2.5 have been reported for
different end points. The approximate RBE values
obtained in rats of 1.4-1.5 for mortality and car-
cinogenesis were well within the range reported for
mice. This range of RBE values would seem to con-
firm a previous suggestion of Bond (ref. 15) that
the RBE of 2.2 GeV protons may depend upon the cri-
terion of biological effect under study.
Jesseph, etal. (rcf. 2), Montour, et al.
(ref. 13) and Stoner, etal. (ref. 14) all give
reasons for interpreting their data on 2.2 GeV
protons as being consistent with what would be ex-
pected from low LET radiation. The current data
obtained in the rat on carcinogenesis, interaction
of protons and gamma-rays on carcinogenesis, acute
mortality and chemical protection against acute
mortality also are consistent with low LET radia-
tion effects. On the other hand, Jesseph, etal.
suggest that as the diameter of the absorbing mat-
erial is increased, it is possible that a high LET
component may become relatively important although
biological data on this point are too fragmentary
at the present time to allow a conclusion to be
reached on this point. All and all, it seems reas-
onable to think that 2.2 GeV protons act largely as
low LET radiation but it must be admitted that the
question of a high LET component must remain open.
SU_4ARY
A single exposure of 42-day-old female Sprague
Dawley rats to 92 rads of 2.2 GeV protons produced
over 365 days an incidence of mammary neoplasia
that was qualitatively and quantitatively similar
to the neoplastic response to 158 rads of 60Co
garmm-rays. Both radiations, when combined, appear.
ed to produce an additive neoplastic response. It
was suggested that 2.2 GeV protons are approximate-
ly 1.5 times more effective than 60Co gamma-rays.
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Acute mortality produced by 2.2 GeV protons and
Co gamma-rays was qualitatively similar and the
proton irradiation appeared to be about 1.4 times
more effective than gamma irradiation. A small re-
duction in acute mortality and a small increase in
mean survival time was produced when AET was admin-
istered before 2.2 GeV proton irradiation. All of
these data were interpreted as indicating that 2.2
GeV proton irradiation produces carcinogenesis and
acute mortality in the rat by a mode of action that
is similar to that of low LET radiation.
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